WO2009028420A1 - 冠動脈の描出能改善剤 - Google Patents

冠動脈の描出能改善剤 Download PDF

Info

Publication number
WO2009028420A1
WO2009028420A1 PCT/JP2008/065022 JP2008065022W WO2009028420A1 WO 2009028420 A1 WO2009028420 A1 WO 2009028420A1 JP 2008065022 W JP2008065022 W JP 2008065022W WO 2009028420 A1 WO2009028420 A1 WO 2009028420A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
coronary artery
extractability
improving
improving coronary
Prior art date
Application number
PCT/JP2008/065022
Other languages
English (en)
French (fr)
Inventor
Masaharu Hirano
Shinichi Kikawa
Kenzou Nakao
Morito Akisada
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Priority to JP2009530085A priority Critical patent/JP5648287B2/ja
Priority to KR1020107003097A priority patent/KR101516452B1/ko
Publication of WO2009028420A1 publication Critical patent/WO2009028420A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　造影剤と組み合わせてなる診断用剤であって、マルチスライスヘリカルＣＴによる冠動脈の画像診断において明瞭な画像を得るために、非手術時における心拍数の高い患者に対して、患者の体重１ｋｇあたり約0.05mg～約2mgの塩酸ランジオロールを、投与工程１回かつ１分間で静脈内投与する剤が、安全でかつ所望の冠動脈描出能改善効果を有する。
PCT/JP2008/065022 2007-08-24 2008-08-22 冠動脈の描出能改善剤 WO2009028420A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009530085A JP5648287B2 (ja) 2007-08-24 2008-08-22 冠動脈の描出能改善剤
KR1020107003097A KR101516452B1 (ko) 2007-08-24 2008-08-22 관동맥의 묘출능 개선제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007217805 2007-08-24
JP2007-217805 2007-08-24

Publications (1)

Publication Number Publication Date
WO2009028420A1 true WO2009028420A1 (ja) 2009-03-05

Family

ID=40387142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065022 WO2009028420A1 (ja) 2007-08-24 2008-08-22 冠動脈の描出能改善剤

Country Status (3)

Country Link
JP (2) JP5648287B2 (ja)
KR (1) KR101516452B1 (ja)
WO (1) WO2009028420A1 (ja)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014042A1 (ja) * 2003-08-08 2005-02-17 Ono Pharmaceutical Co., Ltd. 短時間型β遮断薬を有効成分とする心拍数減少剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014042A1 (ja) * 2003-08-08 2005-02-17 Ono Pharmaceutical Co., Ltd. 短時間型β遮断薬を有効成分とする心拍数減少剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SHIGEO KATO ET AL.: "Shujutsuki ni Okeru Ensan Landiolol Bolus Toyo no Yuyosei", THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA, vol. 23, no. 8, 2003, pages S238 *
SHIN`ICHI HATTORI ET AL.: "Shujutsuji no Hossasei Joshitsusei Hinpaku ni Taishi Ensan Landiolol no Tankai Toyo ga Yuko de Atta Shorei", GENDAI IRYO, vol. 36, no. 1, 2004, pages 282 - 285 *
YASUO KOBAYASHI ET AL.: "Jutsuchu no Joshitsusei Hinmyaku ni Taishite Landiolol ga Yuko de Atta Shinshikkan Gappei 3 Shorei", THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA, vol. 23, no. 8, 2003, pages S239 *
YOSHIHIRO SANDA ET AL.: "Coronary CTA Kensaji no Jochuyo Tanjikan Sayogata beta1 Sentakuteki Shadanyaku Bolus Toyo no koka to Anzensei ni Tsuite", JAPAN RADIOLOGICAL SOCIETY SOKAI SHOROKUSHU, vol. 67TH, 2008, pages S165 *

Also Published As

Publication number Publication date
JP5648287B2 (ja) 2015-01-07
KR20100051653A (ko) 2010-05-17
JP2014208713A (ja) 2014-11-06
KR101516452B1 (ko) 2015-04-30
JPWO2009028420A1 (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
Veekash et al. Carbon dioxide pneumoperitoneum, physiologic changes and anesthetic concerns
CN101601679A (zh) 一种烟酰胺单核苷酸的应用
KR20150050595A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
RU2010132580A (ru) Способы и составы для лечения субарахноидального кровоизлияния коронарной и артериальной аневризмы
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
Baumgartner Rocuronium and sugammadex in myotonic dystrophy.
JP2006514665A5 (ja)
Simonsen Haemodynamic effects of ICI 118,587 in cardiomyopathy.
Hirayama et al. Effects of the addition of low-dose ketamine to propofol anesthesia in the dental procedure for intellectually disabled patients
JP5566521B1 (ja) 膀胱・尿道協調不全改善剤
Park et al. Prolonged paradoxical air embolism during intraoperative intestinal endoscopy confirmed by transesophageal echocardiography-A case report
WO2009028420A1 (ja) 冠動脈の描出能改善剤
Huang et al. Hemodynamic effects of synephrine treatment in portal hypertensive rats
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
Vadivelan et al. The'golden hour'in paraquat poisoning
JP2009531367A5 (ja)
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
WO2007074170A3 (en) Compositions and methods for the treatment and prevention of disease
El-Jabali et al. Talc Retinopathy
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
CN1165000A (zh) 缓解由缺血引起的组织损伤的方法
Hirayama et al. High stakes anesthesia: Anesthetic considerations and implications for complete dental extraction in a patient with complex comorbidities
Lee et al. Unexplained perioperative hypotension in a patient treated with pine needle extract
RU2024103474A (ru) Фармацевтическая композиция для визуализации
Pertseva et al. An experience of application of Amoxicilline/clavulanic acid (Amoxiclav®) in patients with exacerbation of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828744

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20107003097

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009530085

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08828744

Country of ref document: EP

Kind code of ref document: A1